Top

International Journal of Clinical Oncology

Published in:

01-10-2012 | Case Report

A case of ovarian mucinous adenocarcinoma in a premenarcheal girl

Authors: Yoko Matsushita, Yoshihito Yokoyama, Ryousuke Taniguchi, Kazuhiro Abe, Jun Watanabe, Hideki Mizunuma

Published in: International Journal of Clinical Oncology | Issue 5/2012

Abstract

We report a case of a 12-year-old premenarcheal girl who developed ovarian mucinous adenocarcinoma. The tumor, which originated from the right ovary, weighed 1400 g, and had a smooth surface and thin capsule, was extirpated. The cut surface showed multilocular cysts of various sizes and yellowish gelatinous to solid parts that accounted for approximately 40% of the cut surface. The histological findings showed a continuous mixture of mucinous adenoma, mucinous borderline tumor, and mucinous adenocarcinoma with an expansile invasive pattern. It was assumed that an ovarian mass developed in an early period after birth or infancy, and the mutation of certain oncogens occurred in an early period, leading to cancer. While some etiological hypotheses concerning ovarian carcinogenesis have been suggested, we believe this case provides valuable information when considering a new onset mechanism of ovarian epithelial malignant tumors.

Sri Paran T, Mortell A, Devaney D et al (2006) Mucinous cystadenoma of the ovary in perimenarchal girl. Pediatr Surg Int 22:224–227PubMedCrossRef

Morowitz M, Huff D, von Allmen D (2003) Epithelial ovarian neoplasms in children: a retroperitoneal analysis. J Pediatr Surg 38:331–335PubMedCrossRef

Hernandez E, Rosenshein NB, Parmley TH (1982) Mucinous cystadenocarcinoma in a premenarchal girl. South Med J 75:1265–1267PubMedCrossRef

Shankar KR, Wakhlu A, Kokai GK et al (2001) Ovarian adenocarcinoma in premenarchal girls. J Pediatr Surg 36:511–515PubMedCrossRef

Karaman A, Azili MN, Boduroglu EC et al (2008) A huge ovarian mucinous cystadenoma in a 14-year-old premenarchal girl: review on ovarian mucinous tumor in premenarchal girls. J Pediatr Adolesc Gynecol 21:41–44

Center for Cancer Control and information Services. National Cancer Center, Japan. Cancer morbidity data according to the national estimate of the morbidity based on regional cancer registration (1975–2000): data source (National estimate of the morbidity based on regional cancer registration). http://www.ncc.go.jp/jp/cis/index.html

Lukanova A, Kaaks R (2005) Endogenous hormones and ovarian cancer: epidemiology and current hypothesis. Cancer Epidemiol Biomark Prev 14:98–107

Calle EE, Rodriguez C, Walker-Thurmond K et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRef

Lacey JV Jr, Mink PJ, Lubin JH et al (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334–341PubMedCrossRef

10.

Kurian AW, Balise RR, McGuire V et al (2005) Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 96:520–530PubMedCrossRef

11.

Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRef

12.

Kobayashi H, Sumimoto K, Moniwa N et al (2007) Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17:37–43PubMedCrossRef

13.

Konishi I, Kuroda H, Mandai M (1999) Review: gonadotropins and development of ovarian cancer. Oncology 57:45–48PubMedCrossRef

14.

Beral V, Hermon C, Peto R et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314PubMedCrossRef

15.

Hankinson SE, Hunter DJ, Colditz GA et al (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270:2813–2818PubMedCrossRef

16.

Chang ET, Lee VS, Canchola AJ et al (2007) Diet and risk of ovarian cancer in the California Teachers Study Cohort. Am J Epidemiol 165:802–813PubMedCrossRef

17.

Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 17:163CrossRef

18.

Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721PubMed

19.

Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467PubMedCrossRef

20.

Kurman RJ, Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433–443PubMedCrossRef

21.

Sato N, Tsunoda H, Nishida M et al (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in being endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrial carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052–7056PubMed

22.

Jiang X, Morland SJ, Hitchcock A et al (1998) Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58:1707–1712PubMed

23.

Cuatrecasas M, Villanueva A, Matias-Guiu X et al (1997) K-ras mutations in ovarian mucinous tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79:1581–1586PubMedCrossRef

24.

Guan RJ, Fu Y, Holt PR et al (1999) Association of K-ras mutation with p16 methylation in human colon cancer. Gastroenterology 116:1063–1071PubMedCrossRef

25.

Tannapfel A, Benicke M, Katalinic A et al (2000) Frequency of p16^(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47:721–727PubMedCrossRef

26.

Njim L, Moussa A, Saidani Z et al (2010) Bilateral ovarian serous borderline tumor with a giant non-invasive peritoneal implant in a four-year-old girl. J Pediatr Adolesc Gynecol 23:e1–e4PubMedCrossRef

Title: A case of ovarian mucinous adenocarcinoma in a premenarcheal girl
Authors: Yoko Matsushita
Yoshihito Yokoyama
Ryousuke Taniguchi
Kazuhiro Abe
Jun Watanabe
Hideki Mizunuma
Publication date: 01-10-2012
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2012
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0333-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

Risk stratification of survival by lymphovascular invasion, pathological stage, and surgical margin in patients with bladder cancer treated with radical cystectomy

Cigarette smoke stimulates VEGF-C expression in cervical intraepithelial neoplasia (CIN) 1 and 2 lesions

Molecular-targeted therapies for ovarian cancer

Prognostic significance of breast cancer subtype and p53 overexpression in patients with locally advanced or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapy

Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 cases

A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer